General
Preferred name
RIMONABANT
Synonyms
SR 141716A ()
SR141716 ()
SR 151716A ()
Rimonabant (SR141716) ()
SR 141716 hydrochloride ()
SR141716A ()
Rimonabant (Hydrochloride) ()
SR 141716A (Hydrochloride) ()
RIMONABANT HYDROCHLORIDE ()
Rimonabant-d10 ()
ACOMPLIA ()
ZIMULTI ()
SR-141716 ()
SR-141716A ()
SR-14171 ()
[3H]rimonabant ()
P&D ID
PD009325
CAS
158681-13-1
168273-06-1
929221-88-5
Tags
available
drug
Approved by
EMA
First approval
2006
Drug indication
Obesity
Drug Status
approved
withdrawn
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Rimonabant Hydrochloride (SR 141716A Hydrochloride) is a highly potent and selective central cannabinoid receptor (CB1) antagonist with an Ki of 1.8 nM. Rimonabant Hydrochloride (SR 141716A Hydrochloride) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).
PRICE
61
TOXICITY
Almost twice as many people discontinued rimonabant compared with placebo because of adverse events (13.8% vs. 7.2%). These consistently involved psychiatric disorders (8.5% vs. 3.2%), including depression and anxiety. Other common side effects included insomnia, nausea, vomiting, diarrhoea and fatigue.; ;
DESCRIPTION
EMA-only approval in 2007 withdrawn on 16 January 2009
(GtoPdb)
DESCRIPTION
Rimonabant (SR141716) is a highly potent, brain penetrated and selective central cannabinoid receptor (CB1) antagonist with a Ki of 1.8 nM. Rimonabant (SR141716) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).
PRICE
35
DESCRIPTION
Rimonabant hydrochloride (SR 141716A) is a cannabinoid receptor antagonist, binding selectively to central cannabinoid receptors (CB1) with high affinity.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Rimonabant (SR141716) is an inverse agonist for the cannabinoid receptor CB1. It is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. Its main avenue of effect is a reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
3
Compound Sets
28
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
EUbOPEN Chemogenomics Library
Ki Database
LSP-MoA library (Laboratory of Systems Pharmacology)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
59
Molecular Weight
462.08
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
3
cLogP
5.94
TPSA
50.16
Fraction CSP3
0.27
Chiral centers
0.0
Largest ring
6.0
QED
0.52
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
ACAT
Bacterial
CB
hCB1
hCB2
CB1
CNR1, GPR55
CB1 antagonist
Cannabinoid Receptor
Acyltransferase,Bacterial,Cannabinoid Receptor,MmpL3,Transferase
MOA
Cannabinoid Receptor antagonist
CNR1 antagonist
Cannabinoid CB1 Inverse Agonists
IL-6 production inhibitor
Member status
member
ATC
A08AX01
Toxicity type
neurological
Pathway
GPCR/G protein
Metabolism
Microbiology/virology
Anti-infection
Neuronal Signaling
Therapeutic Class
Antiobesity Agents
Recommended Cell Concentration
100 nM
Source data
